Modern technologies have made the sequencing of personal genomes routine. They have revealed thousands of nonsynonymous (amino acid altering) single nucleotide variants (nSNVs) of protein-coding DNA per genome. What do these variants foretell about an individual's predisposition to diseases? The experimental technologies required to carry out such evaluations at a genomic scale are not yet available. Fortunately, the process of natural selection has lent us an almost infinite set of tests in nature. During long-term evolution, new mutations and existing variations have been evaluated for their biological consequences in countless species, and outcomes are readily revealed by multispecies genome comparisons. We review studies that have investigated evolutionary characteristics and in silico functional diagnoses of nSNVs found in thousands of disease-associated genes. We conclude that the patterns of long-term evolutionary conservation and permissible sequence divergence are essential and instructive modalities for functional assessment of human genetic variations.
Evolutionary genomic medicine Thousands of individuals in the general public have begun to gain access to their genetic variation profiles by using directto-consumer DNA tests available from commercial vendors; these tests profile hundreds of thousands of genomic markers at a cost of a few hundred dollars ( Figure 1a ). Through this genetic profiling individuals hope to learn about not only their ancestry but also about genetic variations underlying their physical characteristics and predispositions to diseases. In biomedicine, scientists have been profiling genome-wide variations in healthy and diseased individuals in a variety of disease contexts and populations. This has led to the discovery of thousands of disease-associated genes and DNA variants [1] [2] [3] [4] [5] [6] . Meanwhile, following sharp declines in the per-base cost of sequencing, complete genomic sequencing of individuals and cohorts is underway and expanding { [7] [8] [9] [10] [11] ; 1000 Genomes Project (www.1000genomes.org); Personal Genomes Project (www.personalgenomes.org)}. Taken together, these efforts have begun to paint a more robust picture of the amount and types of variations found within and between human individuals and populations. Any one personal genome contains more than a million variants, the majority of which are single nucleotide variants (SNVs) (Figure 1b ). With the complete sequencing of each new genome, the number of novel variants discovered is decreasing, but the total number of known variants is growing quickly (Figure 2a ). Our knowledge of the number of disease genes and the total number of known diseaseassociated SNVs has grown with these advances [12] .
Today, the vast majority of the known disease-associated variants are found within protein-coding genes ( Figure 1c ) although genome-wide association studies beginning to reveal thousands of non-coding variants. Proteins are encoded in genomic DNA by exon regions, and these comprise only 1% of the genomic sequence (exome; Glossary) [11, 13] . It is this part of our genome for which we have the best understanding of how DNA sequence relates to function, and is arguably the best chance to connect genetic variations with disease pathophysiology. The exome of an individual carries about 6000-10 000 amino-acid-altering nSNVs [2, 7, 9, 10, 14] . These protein alleles are already known to be associated with more than 1000 major diseases [12] . A large number of exome projects are poised to reveal protein mutations of tens of thousands of individuals from disease cohorts and healthy populations for disorders of various complexities [11, [15] [16] [17] . With the sequencing of each new exome we are currently discovering hundreds of new nSNVs, and this points to the existence of a large number of different protein alleles in the genomes of humans (Figure 2b ). In addition to the variations arising in the germline, protein-coding regions of somatic cancer cells contain tens of thousands of nonsynonymous mutations of somatic and germline mutational origins (Figure 1c) . Adding to the variation in the nuclear genetic material are mutations in the mitochondrial genome, many of which are also implicated in diseases (Figure 1c) .
Translating a personal variation profile into useful phenotypic information (e.g. relating to predisposition to disease, differential drug response, or other health concerns) is a grand challenge in the field of genomic medicine. Genomic medicine is concerned with enabling healthcare that is tailored to the individual based on genomic information [18] . This is a daunting task because common variants derived from large population-based studies typically describe relatively small proportions of disease risk. In addition, each individual genome carries many private variants that are not typically seen in a limited sampling of the human populations. Although only a small fraction of all personal variations are likely to modulate health, the sheer volume of genomic and exomic variants is far too large to apply traditional laboratory or experimental techniques to aid in their diagnosis. Higher-throughput techniques are now becoming available to evaluate the functional consequences of hundreds of specified mutant proteins, or much greater numbers of random mutants. However, these methods are still inadequate to handle the volume of variation information arising from modern sequencing methods in a scalable or economical manner [19] [20] [21] [22] [23] .
Fortunately, results from the great natural experiment of molecular evolution are recorded in the genomes of humans and other living species. All new mutations and pre-existing variations are subjected to the process of natural selection which eliminates mutants with negative effects on phenotype. Variants escaping the sieve of 900   1  100  10  1,000  10,000  100,000   1  100  10  1,000  10,000  100,000  1000,000   800   700   600   500   400   300   200   100   0  1  3  5  7  9  11  13  15  17  19  21  23  25  27  29  31  33  35  37  39  41  43  45  47 Cross-referenced by rsIDs, disease-related variants were determined using data from the HGMD [12] and VARIMED [96] datasets. (b) The numbers of different types of variants found per human genome [97] . (c) The numbers of known non-synonymous single nucleotide variants (nSNVs) in the human nuclear and mitochondrial genomes that are associated with Mendelian diseases, complex diseases, and somatic cancers. Compared to complex diseases and somatic cancers, nSNVs related to Mendelian diseases account for the most variants discovered to date. Data were retrieved from HGMD [12] , VARIMED [96] , COSMIC [98] , MITOMAP [41] , and HapMap3 [99] resources. (d) The number of nSNVs in each gene related to Mendelian diseases. The majority of genes have only one or a few mutations, whereas some genes host hundreds or even more than 1000 mutations. Data were retrieved from HGMD. The numbers of variants in panels (a-c) are on a log 10 scale. Information for disease-associated variants is shown in red and the personal and population variations are shown in blue.
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natural selection appear in the form of differences among the genomes of humans, great apes, and other species. Through multispecies comparisons of these data, using the models and methods of molecular evolution, it is possible to mine this information and evaluate the severity of each variant computationally (in silico). With the availability of a large number of genomes from the tree of life it is becoming clear that evolution can serve as a type of telescope for exploring the universe of genetic variation. In this evolutionary telescope, the degree of historical conservation of individual position (and regions) and the sets of substitutions permitted among species at individual positions serve as two lenses. This tool has the ability to provide first glimpses into the functional and health consequences of variations that are being discovered by highthroughput sequencing efforts. Consequently, phylomedicine will emerge as an important discipline at the intersection of molecular evolution and genomic medicine with a focus on understanding of human disease and health through the application of long-term molecular evolutionary history. Phylomedicine expands the purview of contemporary evolutionary medicine [24] [25] [26] [27] [28] to use evolutionary patterns beyond the short-term history (e.g. populations) by means of multispecies genomics [29, 30] . In the following we review scientific investigations that have analyzed the evolutionary properties of disease-associated nSNVs and predicted function-altering propensities of individual variants in silico using multispecies data. We have primarily focused on variants of exomes because the function of proteins is currently best understood independently of comparative genomics. Furthermore, protein point mutations are associated with more than 1000 major diseases, and generally with a statistically significant association beyond chance alone. Furthermore, the cost of exome sequencing is declining to the point that a legion of small scientific laboratories are now able to economically profile complete exomes [17, 31, 32] . Therefore, the chosen emphasis on exome variations reflects current directions in clinical and research applications of genomic sequencing.
Mendelian (monogenic) diseases
For centuries it has been known that particular diseases run in families, notably in some royal families where there was a degree of inbreeding. Once Mendel's principles of inheritance became widely known in the early 1900s it became evident from family genealogies that specific heritable diseases fit Mendelian predictions. These are termed Mendelian diseases (reviewed in [33] ). Such diseases can have substantial impact on the affected individual but tend to be rare, on the order of one case per several thousand or several tens of thousands of individuals.
Over the last three decades mutations in single (candidate) genes in many families have been linked to individual Mendelian diseases (e.g. Box 1). Sometimes more than a hundred SNVs in the same gene have been implicated in a particular disease (Figure 1d ). For example, by the turn of this century, individual patient and family studies revealed that over 500 different nSNVs in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can cause cystic fibrosis (CF). This enabled first efforts to examine evolutionary properties of the positions harboring CFTR nSNVs [29] . The disease-associated nSNVs were found to be overabundant at positions that had permitted only a very small amount of change over evolutionary time [29] (Figure 3a , b). Soon after, this trend was confirmed at the proteome scale in analyses of thousands of nSNVs from hundreds of genes ( Figure 3c ) [34] [35] [36] [37] . These patterns were in sharp contrast to the variations seen in non-patients, which are enriched in the fast-evolving positions ( Figure 4a ) [29, 35] . In population polymorphism data, faster-evolving positions also show higher minor-allele frequencies than those at slow-evolving positions [29, 35] , which translates into an enrichment of rare alleles in slowly evolving and functionally important genomic positions [38] .
Looking at patterns of evolutionary retention at positions, another type of evolutionary conservation, a similar pattern was found: positions preferentially retained over the history of vertebrates were more likely to be involved in Mendelian diseases as compared to the patterns of natural variation ( Figure 4b ) [35] . Somatic mutations in a variety of cancers have also been found to occur disproportionately at conserved positions [39, 40] . A similar pattern has emerged for mitochondrial disease-associated nSNVs [41] .
The relationship between evolutionary conservation and disease association has been explained by the effect of natural selection [29, [34] [35] [36] [37] . There is a high degree of purifying selection on variation at highly conserved positions because of their potential effect on inclusive fitness (fecundity, reproductive success) due to the functional importance of the position [29, 34, 35, 37, 38] . At the The number of novel SNVs discovered by sequencing one or more genomes [97] . With increasing numbers of genomes sequenced, the number of novel SNVs decreases (bars), whereas the cumulative count of SNVs increases (filled circles). (b) The number of nSNVs discovered by sequencing one or more exomes [14] . With more exomes sequenced, the number of novel SNVs discovered decreases (bars) and the cumulative count of nSNVs increases (filled circles). Panels (a) and (b) are redrawn with permission from [97] and [14] , respectively.
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faster-evolving positions, many substitutions have been tolerated over evolutionary time in different species. This points to the 'neutrality' of some mutations that spread through the population primarily by the process of random genetic drift and appear as fixed differences between species. Therefore, fewer mutations are culled at fast-evolving positions, producing a relative under-abundance of disease mutations at such positions. Of course, the above arguments hold true only when the functional importance of a position has remained unchanged over evolutionary time, an assumption that is expected to be fulfilled for a large fraction of positions in orthologous proteins.
Multigenic (complex) diseases
Despite successes in identifying and mapping genes causing Mendelian diseases, it is now clear that most common diseases with significant genetic components, although they are often seen to cluster in families, do not approximate to the simple paradigm of high penetrance based on a dominant/recessive genotype. Instead, common diseases appear to result from a more complex pattern where many genes, and probably other non-genetic factors, contribute in non-additive ways, and individual monogenic factors have a low and inconsistent correlation with the disease phenotype [42] [43] [44] . Examples of such diseases include heart disease, asthma, rheumatoid arthritis, and type 2 diabetes [45] [46] [47] [48] [49] . These diseases often appear relatively later in life, and the associated nSNVs are often present in one or more human populations at substantial frequencies. An early examination of the evolutionary patterns of the occurrence of a small set of 37 nSNVs associated with complex diseases did not find any tendency for these variations to occur at sites with high conservation (Figure 4c ) [37] . These trends were confirmed with larger datasets containing alleles associated with seven complex diseases [50] . These patterns stand in stark contrast to those seen for Mendelian diseases. At the level of overall rate of protein evolution, the genes associated with complex diseases are not under strong purifying selection as compared to the proteins implicated in the Mendelian diseases [51] . The rate of nonsynonymous substitutions in complex-disease genes is more than twice that of the Mendelian disease genes [52] . One reason for the lack of evolutionary conservation of positions associated with complex diseases is that their effects appear later in life, which means that these variants are frequently inherited without being acted upon by natural selection and without any impact on fecundity. For this reason, molecular evolutionary analyses are sometimes not deemed to be useful for complex diseases [53] .
Evolutionary and biochemical constraints on diseaseassociated nSNVs In addition to the evolutionary conservation of the positions in the protein, the biochemical properties of the amino acid change can also provide rich information. Not all changes at a position have an equal effect because one set of amino acid alternatives could be optimal, another set tolerable, and a third crippling to protein structure and function. Although the actual effect of a mutation is expected to be a complex function of the protein structure and its cellular milieu, many biologists have used a simple measure of biochemical difference (Grantham distance [54] ) to quantify the severity of amino acid changes. In
Miller syndrome is a rare genetic disorder characterized by distinctive craniofacial malformations that occur in association with limb abnormalities ( Figure I on the left; reproduced with permission from [102] ). It is a typical Mendelian disease that is inherited as an autosomal recessive genetic trait. By sequencing the exomes of four affected individuals in three independent kindreds, ten mutations in a single candidate gene, DHODH, were found to be associated with this disease [102] . In the figure on the right, the ten mutations are shown in the context of the DHODH orthologs from six primates (including human) and the timing of their evolutionary relationships (timetree from [57] ). They are in slow-evolving sites that are highly conserved not only in primates, but also among distantly related vertebrates. Specifically, 50% of these mutations are found at completely conserved positions among 46 vertebrates, including human. The average evolutionary rate, estimated using methods in [57] , for sites containing these disease-related mutations is 0.50 substitutions per billion years, which is 40% slower than those sites hosting four non-disease-related population polymorphisms of DHODH available in the public databases. Biochemically, the average severity of these ten mutations is more than twice that of the four population polymorphisms, as measured using the Grantham's [54] index (112 and 55, respectively). PolyPhen-2 [103] , a computational program used to predict the propensity of individual amino acid changes to damage protein function, diagnosed all ten mutations to be potentially damaging and the four population polymorphisms to be benign. This case study demonstrated clear patterns of long-term evolutionary conservation for Mendelian diseaselinked variations, and the promising applications of in silico tools in assisting functional diagnosis. an analysis of seven genes it was noted early on that amino acid changes of Mendelian disease-associated nSNVs were, on average, 67% more severe than substitutions observed between species in the same proteins [29] . The generality of this trend was confirmed in subsequent analyses of a larger number of Mendelian disease genes [34, 35] . Interestingly, the timing of the onset of a disease also shows a correlation with the biochemical severity of an amino acid change: late-onset diseases involve amino acids with smaller biochemical differences [35] . Similarly, the severity of the phenotype also shows a relationship with the biochemical dissimilarity of the variation (e.g. [55] ). In addition, the severity of Mendelian nSNVs has been quantified by using the substitution probability of one amino acid into another. These analyses show that disease-associated nSNVs are amino acid changes that are unlike those observed between species proteome-wide (e.g. [29, 34] ). Conversely, a shift towards the right in complex disease nSNVs indicates lower evolutionary conservation, which overlaps with normal variations observed in the population. Data for the neutral model (black line) were generated by simulation [37] . Panels (a-c) are redrawn with permission from [35] , [35] , and [37] , respectively. A large number of Mendelian disease-associated variations occur at positions that show evolutionary substitutions among species. For example, more than a hundred variants of the CFTR protein in CF patients occur at positions that have undergone at least one change (Figure 3a) . In any position, evolutionary differences (substitutions) between species are expected to be neutral in nature, in other words they are unlikely to have negative fitness effects provided that the protein function has not changed. They constitute a set of evolutionarily permissible alleles (EPAs) at a given position, which are expected to not be involved in diseases at those positions. Indeed, an overwhelming fraction of Mendelian nSNVs (90%) are not evolutionarily permissible [35, 55, 56] . This is in sharp contrast to population polymorphisms that frequently (59%) appear in the set of EPAs in individual positions [57] . Disease-associated nSNVs in mitochondrion-encoded proteins also show similar patterns [58] .
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Nevertheless, scientists have been interested in investigating why some nSNVs are associated with diseases in humans, but appear as natural alleles in other species [35, 56, 58, 59] . One possibility is that the function of the affected amino acid position has changed either in humans or in other species. In this case, evolutionary differences among species cannot be used to determine permissible amino acids at the affected positions. Another reason for the overlap between the disease nSNVs and evolutionarily permissible alleles is that the amino acid position has undergone compensatory changes. In this case the negative effects of the mutation(s) at one position of the same or different proteins compensates for the negative effects of the other mutation [35, 56, [59] [60] [61] . Such compensation could occur, for example, by antagonistic pleiotropy [62, 63] or for protein functional reasons (e.g. [64, 65] ). Whatever the reason, the initial mutation needs to escape natural selection for a period of time before it is compensated by another mutation in the same or another protein. This is likely to be possible only for mutations that have very small negative fitness effects, resulting in such mutations occurring at faster-evolving positions that are biochemically less radical (e.g. [35] ).
Evolutionary diagnosis of function-altering mutations in silico Over a decade ago, first methods were proposed to predict computationally whether a mutation will negatively affect the structure and function of a human protein [30, [66] [67] [68] . These methods, now part of the PolyPhen software package, employed physical properties of the mutational change along with a multispecies alignment as a basis to evaluate mutations. This method showed promise: 69% of mutations associated with human disorders could be correctly diagnosed to be damaging to protein function (true positives) and 66% of known population polymorphisms were correctly diagnosed as non-damaging (true negatives) [67] . Most recently, a true-positive rate of 92% was achieved by PolyPhen-2 when only damaging alleles with known effects on the molecular function causing Mendelian diseases were tested [63] , which reduced to 73% when all human disease-associated mutations were analyzed. The false-positive rate was close to 20% for PolyPhen-2.
Another early method [sorting intolerant from tolerant (SIFT)] employed multispecies alignments to distinguish between functionally neutral and deleterious amino acid changes [69] . Applications of SIFT and PolyPhen/PolyPhen-2 to predict well-characterized variants in selected [85] . The ROC curve for Condel rises much more quickly, which means that it has a much greater rate of diagnosing damaging variants (true positives) at the expense of much smaller rate of incorrect diagnosis (false positives). (c) The relationship of the accuracy of the PolyPhen prediction for disease-associated nSNVs at positions evolving with different long-term rates (0-5 are categories of slowest to fastest-evolving sites) [57] . This shows that the accuracy of the PolyPhen prediction is the highest for the most slow-evolving positions for disease-associated nSNVs. Panels (a-c) are redrawn with permission from [2] , [57] , and [85] , respectively.
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sets of genes revealed similar true-positive rates for the two programs [70, 71] , but these investigations revealed much higher false-positive rates (up to 68%). Comparative analyses have also revealed that the prediction accuracy of in silico tools depends on both the algorithm and the sequence alignment employed [71] [72] [73] , with predictions from the PolyPhen-2 showing the least dependence on the alignment employed.
Over the years these in silico prediction tools have frequently been employed to predict the proportion of benign mutations in newly sequenced human genomes and to prioritize polymorphisms for further experimental research in humans and other species [74] [75] [76] [77] [78] [79] [80] [81] . In all of these investigations the focus has been on diagnosing monogenic disease mutations because in silico tools based on evolutionary considerations are not expected to be effective for identifying nSNVs associated with complex diseases. The patterns of evolutionary conservation of known complex disease nSNVs are no different from those of natural polymorphisms found among populations (Figure 4c ).
Even for Mendelian disease mutations, in silico diagnosis has been challenging because the diagnoses from different programs are not the same for the same variant. For example, PolyPhen and SIFT diagnoses for protein-altering mutations in the Venter genome disagreed more often than they agreed [2] (Figure 5a) . Because of such problems, efforts have gone into the development of composite and ensemble methods that: (i) incorporate increasingly larger numbers of clinical and biological attributes in the decision-making process, and (ii) combine the results from existing tools by using logistic regression, Bayesian neutral networks, decision trees, support vector machines, random forests, and multiple selection rule voting [82] [83] [84] [85] . These efforts are beginning to improve prediction accuracy significantly, and one recent method combining many less successful methods into a new composite approach was found to outperform each method used separately (Figure 5b ) [85] .
Many evolutionary features used by classical and advanced versions of SIFT and PolyPhen (among others) for diagnosing Mendelian disease variants are also discriminatory for differentiating between driver and passenger mutations [39, 86] . This prompted the development of a hybrid method, CanPredict [86] , that integrated gene function information (e.g. gene ontology) to screen somatic mutations (also [87] ). This tool diagnoses mutations found in samples of more than ten patients to be damaging 50% more often than mutations that were seen in only one patient [86] . Driver mutations contribute to cancer progression and have a tendency to be found in many independent samples as compared to passenger mutations that, as the name suggests, hitchhike causing the cells with driver mutations to increase in number by the processes of natural selection and adaptation [39, 40, [88] [89] [90] . For mitochondrial DNA (mtDNA), four different tools (including PolyPhen and SIFT) have been combined along with the biochemical features and frequency of variants to evaluate mitochondrial nSNVs [91] . This approach was adopted because only 5% of disease-associated nSNVs in mtDNA were found to be harmful by all four in silico methods, even though each of these SNVs was predicted to be damaging by at least one method [91] .
Efforts have been made to identify a priori determinants of the protein position where in silico tools will most probably succeed [57] . This knowledge will empower biologists to quantify the reliability of inference and use the in silico predictions only when they are expected to be reliable. Initial research has revealed a clear-cut relationship between the sensitivity (true-positive diagnosis) and specificity (true-negative diagnosis) of predictions with the rate at which the given position has evolved over species as diverse as fish and lamprey. The disease-associated nSNVs at slow-evolving positions were more likely to be diagnosed correctly than those at fast-evolving positions (Figure 5c ). This is consistent with earlier findings that the evolutionary rate is overwhelmingly the most important determinant of the accuracy of in silico prediction methods [92, 93] . It is also clear that the accuracy of in silico tools is severely degraded when the observed disease-associated variant is found in other species at the same position [57] . Therefore, the in silico diagnosis failures are systematic and are probably predictable.
By using evolutionary rates derived from multispecies analyses a priori, it should be possible to develop adaptive classifiers that have potential to generate more reliable predictions based on the evolutionary context of specific positions. Because high-quality genomic alignments between human and many closely and distantly related species are publicly available, it is possible to enumerate each multispecies aligned position in the human genome to compute position-specific features such as evolutionary rate of change. These pre-computed evolutionary features could be incorporated into prediction methods to adaptively adjust the classifier thresholds to optimize for the type of nSNVs that are likely to be observed. For example, fastevolving positions are expected to harbor a higher proportion of neutral nSNVs, and thresholds could therefore be fine-tuned to improve overall accuracy.
Concluding remarks
The cosmic analogy used in the title of this review is intended to convey the enormity of the challenge that researchers in genomic medicine face as they attempt to decipher the functional consequences of the constellation of genomic changes carried in each personal genome. In tackling this challenge the evolutionary telescope is among a set of initial tools to generate functional predictions. Clearly, the progress made to date prompts enthusiasm, but there is an urgent need to develop better in silico approaches to aid and complement the array of experimental, clinical, and physical tools that must be combined to assay accurately the diversity of the functional effects of the variants present in the human population and of the de novo mutations that continually arise in the natural processes of cell division and population propagation.
Many limits to the use of the evolutionary approaches in genomic medicine are already evident. As mentioned earlier, in silico analysis of nSNVs underlying complex diseases remains a major challenge. Furthermore, there are few cases when disease categorization can be seen as a black and white decision: diseases represent a continuum
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Trends in Genetics September 2011, Vol. 27, No. 9 from predominately monogenic to highly polygenic [94] . Some classical monogenic diseases will surely be caused by mutations in multiple genes, whereas some classic polygenic diseases will have a few major effect alleles. This complicates the choice of when to apply evolutionary knowledge in diagnosing the function-altering potential of variants. The distinction between the neutrality and non-neutrality of function alteration is also not straightforward because it depends on both environmental and genomic contexts (e.g. compensatory mutations) and could well involve fitness trade-offs (e.g. between rapid maturation and risk of disease). Moreover, the extent to which personal variations manifest themselves as health concerns in individuals remains unknown. With an enhanced quantification of health and disease, and an improved understanding of genome and disease biology, we will have a better idea of the powers and pitfalls of evolutionary analysis in genomic medicine. At the same time there is a need to profile exome variants experimentally and connect them with individual health via predictive frameworks. Some cell-based and in vitro assays are already showing promise in deciphering the pathogenic roles of variants in cancers [23, 95] , an important step forward towards satisfying the urgent need for the development of higher throughput biological and functional approaches.
Nonetheless, the rapid emergence of clinical genome sequencing has established a pressing need to incorporate evolutionary information into clinical diagnostics. An individual genome contains hundreds of thousands of variants of different antiquities, and the long-term evolutionary history of genomic positions provides an immediate means to derive and apply predictive and quantitative assessement of the potential functional effect of any given variant observed. Using the evolutionary anatomies of positions, clinicians can be provided with ready access to evolutionary-guided in silico diagnostic tools to identify and diagnose the observed variants that are most likely to have consequences for the health or clinical course of treatment for a patient.
